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Figure 3. A highly conserved amino acid sequence in the intracellular
tyrosine kinase domain of the KIT family. Note that the sequence of
MAPESIFNCVYT is almost invariant among the KIT family. Conserved amino
acids are boxed. The arrow indicates the mutation position. The threonine
mutated here is a strictly conserved amino acid residue.
severe phenotype, as compared with the other type of mutations. On
the basis of the above findings, Spritz stated that a hierarchical paradigm
of KIT mutation accounts for a graded series of dominant phenotypes
of piebaldism (Spritz, 1994). Our patient exhibited a typical and
relatively severe piebaldism phenotype. Therefore, our results provide
supportive evidence that a missense mutation within the tyrosine kinase
domain produces a severe phenotype. Incidentally, Ezoe has reported
that pathologic KIT gene mutations or gene deletions were detected
in only 75% of patients with typical piebaldism (Ezoe et al, 1995). It
is important to examine more patients with piebaldism and investigate
the molecular defects in the KIT gene.
Autoantibodies from a Patient with Paraneoplastic Pemphigus
Bind Periplakin, a Novel Member of the Plakin Family
To the Editor:
Paraneoplastic pemphigus (PNP) is a mucocutaneous disorder associated
with neoplasia (Anhalt et al, 1990). It is characterized by mucosal
erosions, polymorphous cutaneous lesions, and variable histologic
features. PNP patients have in situ bound and circulating autoantibodies
that bind to stratified and nonstratified epithelia (Anhalt et al, 1990;
Oursler et al, 1992). Sera from affected patients immunoprecipitate a
complex of proteins with an apparent molecular mass of 250 kDa,
230 kDa, 210 kDa, 190 kDa, 170 kDa, and 135 kDa in a variable
pattern (Anhalt et al, 1990; Oursler et al, 1992; Hashimoto et al, 1995).
It has been suggested that the detected 230 kDa is the bullous
pemphigoid antigen 230 (BP230), the proteins of 250 kDa and 210 kDa
correspond to desmoplakin I (DPI) and II (DPII), respectively, while
the 135 kDa is desmoglein 3 (Anhalt et al, 1990; Oursler et al, 1992;
Hashimoto et al, 1995). Recent studies, however, indicate that the
210 kDa protein bound by some patients’ sera is not DPII, but
envoplakin (ENV) (Kim et al, 1997). We have here investigated the
identity of the proteins targeted by the autoantibodies from a patient
with PNP by combined immunoblot and immunoprecipitation studies.
The 45 y old Caucasian patient fulfilled the criteria of PNP because
he exhibited: (i) a polymorphous eruption with bullous and erosive
lesions of the oral cavity, conjunctivae, trunk, extremities, and genital
area, in association with a history of relapsing Castleman’s tumor;
(ii) histologically, scattered necrotic keratinocytes, vacuolar interface
changes, and a lichenoid infiltration in the upper dermis; (iii) immuno-
pathologically, deposits of C3 in the epidermal basement membrane
associated with deposits of IgG and C3 in the epidermal intercellular
spaces, as well as circulating IgG antibodies that bound the cell
surfaces of human epidermis, stratified squamous epithelium of monkey
esophagus, and transitional epithelium of rat urinary bladder. To
investigate the reactivity of this patient’s serum, mouse IgG monoclonal
antibody (MoAb) against desmoplakin (Boehringer Mannheim AG,
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Rotkreuz, Switzerland) and MoAb against desmoglein 1 (Progen,
Biotechnik GmbH, Heidelberg, Germany) were used. The rabbit anti-
serum CR1 and the anti-serum CR3 against the COOH-terminus of
ENV and periplakin (PER), respectively, were kindly provided by Dr.
F.M. Watt (Imperial Cancer Research Fund, London, U.K.) (Ruhrberg
et al, 1996, 1997). The anti-serum against the COOH-terminal domain
of BP230 was a gift of Dr. J.R. Stanley (Department of Dermatology,
University of Pennsylvania, Philadelphia, PA). Peroxydase-conjugated
goat anti-human IgG (H 1 L) antibody (Institut Pasteur, Marnes la
Coquette, France), goat anti-mouse Ig (Amersham Life Sciences,
Zu¨rich, Switzerland), and goat anti-rabbit IgG (Cappel, West Chester,
PA) were purchased. Immunoblotting studies using bovine tongue
extracts were performed as previously described (Rybojad et al, 1993).
For immunoprecipitation studies cultured human keratinocytes were
incubated with modified Eagle’s medium without methionine and
cysteine (Gibco BRL, Basel, Switzerland) for 1 h at 37°C, then labeled
with 100 µCi (35S) methionine/cysteine (Amersham) per ml for 6 h,
washed, and lyzed with 1% NP-40 in 25 mM Tris-HCl (pH 7.5),
4 mM ethylenediamine tetraacetic acid, 100 mM NaCl, 1 mM
phenylmethanesulfonyl fluoride, 10 µg leupeptin per ml, and 10 µg
soybean trypsin inhibitor per ml. The lysates were clarified by centrifu-
gation and precleared with Protein A-Sepharose CL-4B (Pharmacia
LKB Biotechnology, Uppsala, Sweden). Samples of precleared lysates
were immunoprecipitated with antibodies previously bound to protein
A-Sepharose or to Protein A-Sepharose to which rabbit anti-mouse
IgG was attached (Borradori et al, 1997). The immunoprecipitates
were washed with lysis buffer and with phosphate buffered saline, after
which they were resuspended in sodium dodecyl sulfate-sample buffer,
analyzed on a 5% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis under reducing condition, and processed for fluorography or,
alternatively, electrophoretically transferred to a nitrocellulose sheet for
immunoblotting.
Consistent with previous studies in PNP, the patient’s serum con-
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Figure 1. Circulating IgG from the patient with PNP immunoblots and
immunoprecipitates a complex of antigens. (A) Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis immunoblot analysis of bovine tongue
extracts utilizing the following: MoAb against desmoglein 1 (lane 1), MoAb
against desmoplakin (lane 2), serum from the PNP patient (lane 3), serum from
a normal volunteer (lane 4). (B) Immunoprecipitation studies of biosynthetically
radiolabeled human keratinocytes. The immunoprecipitates were applied to a
5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and studied by
fluorography under reducing conditions. The comparative immunoprecipitation
studies utilized the following: serum from a normal volunteer (lane 1), serum
from the PNP patient (lane 2), anti-serum CR1 against envoplakin (lane 3),
MoAb against desmoplakin (lane 4), anti-serum against the bullous pemphigoid
antigen 230 (lane 5). Molecular mass markers are indicated in kDa.
Figure 2. Immunoblot analysis of the immunoprecipitates demonstrates
that the patient’s IgG recognizes envoplakin and periplakin. The
immunoprecipitates (IP) from radiolabeled cultured keratinocytes utilizing serum
from a normal volunteer (NHS) (lanes 1–3), serum from the PNP patient (PNP)
(lanes 4–6), anti-serum CR1 against envoplakin (lanes 7 and 10), anti-serum
CR3 against periplakin (lanes 8 and 11), MoAb against desmoplakin (DP) (lanes
9 and 12) were processed for immunoblotting (IB). The MoAb against DP did
not blot any proteins in the immunoprecipitates from NHS (lane 1) and PNP
(lane 4). The anti-serum CR1 immunoblotted a protein of 210 kDa in the
immunoprecipitates from PNP (lane 5), but not from NHS (lane 2). The anti-
serum CR3 reacted against a protein of 190 kDa in the immunoprecipitates
from PNP (lane 6), but not from NHS (lane 3). In reciprocal experiments, PNP
immunoblotted two proteins of 210 and 190 kDa in the immunoprecipitates
with the CR1 anti-serum (lane 7) and CR3 anti-serum (lane 8), but not with
the MoAb against DP (lane 9). The NHS did not show any reactivity with the
immunoprecipitates utilizing the CR1 anti-serum (lane 10), the CR3 anti-
serum (lane 11), and the MoAb against DP (lane 12). Molecular mass markers
are indicated in kDa.
tained IgG antibodies that immunoblotted a characteristic doublet of
210 kDa and 190 kDa (Fig 1A) (Rybojad et al, 1993; Hashimoto et al,
1995). The MoAb directed against desmoplakin recognized two bands
of µ250 kDa and 210 kDa corresponding to DPI and DPII, respectively;
however, the electrophoretic mobility of DPII was slightly slower than
that of the 210 kDa protein detected by the patient’s serum, suggesting
that the two proteins were not identical. In comparative immuno-
precipitation studies (Fig 1B), the patient’s serum precipitated from
biosynthetically radiolabeled human keratinocytes a complex of proteins
of 210 kDa, 190 kDa, 170 kDa, and 130 kDa. It is worth noting that
the anti-serum CR1 against ENV as well as the anti-serum CR3
against PER (not shown) coimmunoprecipitated, as previously reported
(Ruhrberg et al, 1996, 1997), a 210 kDa and 190 kDa protein
corresponding to ENV and PER, respectively, that seemed to comigrate
with two of the proteins precipitated by the patient’s serum. As
expected, the MoAb directed against desmoplakin precipitated DPI
and DPII. The electrophoretic mobility of DPII was close to that of
the 210 kDa protein precipitated by the patient’s serum. To further
assess the identity of the 210 kDa and 190 kDa proteins bound by the
patient’s serum, immunoblotting analysis of the immunoprecipitates
was performed (Fig 2). When the samples immunoprecipitated with
the patient’s serum were subjected to immunoblotting with the CR1
anti-serum against ENV and the CR3 anti-serum against PER, proteins
of 210 kDa and of 190 kDa, respectively, were recognized. Alternatively,
when the samples immunoprecipitated with either the CR1 anti-serum
or the CR3 anti-serum were subjected to immunoblotting, the patient’s
serum recognized two proteins of 210 kDa and 190 kDa. In contrast,
when the immunoprecipitates obtained with the anti-desmoplakin
antibody were immunoblotted using the patient’s serum, no reactivity
was observed. The reciprocal experiment yielded similar results. These
results demonstrate that the 210 kDa and 190 kDa proteins bound
by the patient’s serum most likely correspond to ENV and PER,
respectively.
ENV and PER belong in analogy to BP230, DPI, and DPII, to a
family of proteins involved in the organization of intermediate filaments
and cytoskeletal architecture, the plakins (Ruhrberg et al, 1996, 1997).
These two proteins are expressed in keratinizing stratified squamous
epithelia and in a variety of other epithelia. In the epidermis, they are
localized to desmosomes and keratin filaments and are physically
associated precursors of the cornified envelope. It has been suggested
that these two proteins contribute to the mechanical integrity of
desmosomes (Ruhrberg et al, 1996, 1997).
Although passive transfer experiments have indicated that autoanti-
bodies from PNP patients are pathogenic in vivo (Anhalt et al, 1990),
the exact mechanism by which they cause tissue damage remains
unclear. The identification of ENV and PER as distinct target antigens
in PNP raises the possibility that autoantibody-mediated impairment
of their function is involved in the pathogenesis of the disease. In
conclusion, our observations confirm a previous study indicating that
ENV is a component of the antigen complex recognized by PNP sera
(Kim et al, 1997) and further identifies PER as a novel target
antigen in PNP. The findings suggest that PNP represents a distinct
mucocutaneous disorder associated with an autoimmune response to
various members of the plakin family.
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Immunologic Protection Afforded by Sun Screens
To the Editor:
With reference to the Section Editor’s note by Dr. Francis P. Gasparro
and the letter by Drs. Peter Wolf and Margaret Kripke published in
the Journal of Investigative Dermatology (110:183,184) concerning our
original paper in the June issue, we support our original conclusions
and disagree with the opinions expressed by these two groups. Both
groups have criticized our original paper for not calculating the immune
protection factor (IPF). Given the data we generated using five different
sun screens, we would certainly agree with both groups that to produce
an immunosuppression factor we would need to estimate the dose of
ultraviolet (UV) light needed to induce 50% immunosuppression with
and without the sun screens, and to divide the ISD50 obtained with
the sun screen by the ISD50 obtained without sun screens to give an IPF.
We feel, however, that it is very important to point out that an IPF
can in no way equal a sun protection factor (SPF). The erythemal
response and the immunosuppressive response in the skin caused by
UV radiation have very different cellular and molecular mechanisms
and almost certainly different dose–response curves. There is therefore
no way that one can directly compare SPF with IPF. Indeed, do we
really want another label on sun screens that will only confuse the user
further? We already have an SPF that many patients do not understand
and a number of very different ways that companies can choose from
when indicating UVA protection on pack labels, such as the star rating
seen in the U.K. Putting an IPF value as well on bottles would almost
certainly confuse the end user even further. We would emphasize that
with the potential to further cloud the issue, at no point did we try
to ascribe an IPF to the creams used in our study.
The major danger that we foresee is that if a sun screen protects
against UV erythema to a greater extent than it protects against the
immune response, then immunosuppression could result without any
evidence of clinical erythema. This could thus potentially increase the
risk of significant UV induced skin damage such as skin cancer, while
giving the user the false impression that they are protecting themselves
from this damage. The conclusion we drew from our original study
was that all the sun screens that we tested, which had SPF from 3.5
to 5.7, protected the skin immune system beyond the UV dose required
to exceed the SPF of the sun screen. That means that with a sun
screen of SPF 5, skin irradiated with five times the minimal erythema
dose showed no evidence of immunosuppression. Although the IPF is
of obvious scientific interest, the fact that sun blocks will protect
against erythema and immunosuppression to the same dose of UV
light is of far greater clinical importance.
We also feel it is important to point out that in further data that we
Ruhrberg C, Hajibagheri NMA, Simon M, Dooley TP, Watt FM: Envoplakin, a novel
precursor of the cornified envelope that has homology to desmoplakin. J Cell Biol
134:715–729, 1996
Ruhrberg C, Hajibagheri NMA, Parry DAD, Watt FM: Periplakin, a novel component
of cornified envelopes and desmosomes that belongs to the plakin family and forms
complexes with envoplakin. J Cell Biol 139:1835–1849, 1997
Rybojad M, Leblanc T, Flageul B, et al: Paraneoplastic pemphigus: case report in a child
with a T cell lymphoblastic lymphoma. Br J Dermatol 128:418–422, 1993
have generated looking at test formulations of sun screens, we have
identified some formulations of sun screens that do not protect the
immune system to the SPF of the sun screen, and that in these
formulations there is a significant discrepancy between erythemal
protection and immunoprotection. The use of these sun screens
would therefore increase the potential risk of patients developing
immunosuppression related to UV exposure without visible signs of
erythema or sunburn.
There are obvious practical problems in developing an IPF using
the methodology in our paper. Our methodology has the advantage
of using a human system that avoids the inter species variation in
response to UV light and also ethical issues. It does, however, restrict
us in the number of experiments that can be performed. To assess the
IPF for each sun screen that we wish to test, we would require much
larger quantities of skin than we have access to and this would almost
certainly make the procedure impracticable. The technique does,
however, provide for a rapid, easy, reproducible, noninvasive, and
animal sparing technique that can reduce the concern that sun blocks
will protect the skin immune system to the UV irradiation dose that
is equivalent to the UV erythemal dose the patient can achieve using
the sun screens.
In Gasparro’s note there is also a comment about the sensitivity of
our assay compared with that of Cooper et al (1985). We would like
to point out that the study conducted by Cooper et al used the Phillips
FS20 light source that is now known to be contaminated with UVC
and this may contribute to its more significant immunosuppressive
effect. The Phillips FS20 also produces predominately short wavelength
UVB, whereas the light source we use, the Oriel Solar Simulator, does
provide a UV spectral output similar to natural sunlight. Cooper et al
also used different cell numbers in their mixed epidermal lymphocyte
reaction, and studies in our laboratory have shown that lowering the
number of stimulator epidermal cells and responder lymphocytes can
increase the sensitivity of the technique. It does not, however, alter
the end result and should therefore not affect the immunoprotection
afforded by using sun screens.
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